IL300455A - New psilocin derivatives with prodromal properties - Google Patents
New psilocin derivatives with prodromal propertiesInfo
- Publication number
- IL300455A IL300455A IL300455A IL30045523A IL300455A IL 300455 A IL300455 A IL 300455A IL 300455 A IL300455 A IL 300455A IL 30045523 A IL30045523 A IL 30045523A IL 300455 A IL300455 A IL 300455A
- Authority
- IL
- Israel
- Prior art keywords
- psilocin
- ch2ch2
- derivative according
- indol
- disorder
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102020121965.2A DE102020121965A1 (de) | 2020-08-21 | 2020-08-21 | Neuartige Derivate des Psilocins mit Prodrug-Eigenschaften |
| US202063118842P | 2020-11-27 | 2020-11-27 | |
| PCT/EP2021/073303 WO2022038299A1 (en) | 2020-08-21 | 2021-08-23 | Novel psilocin derivatives having prodrug properties |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL300455A true IL300455A (en) | 2023-04-01 |
Family
ID=77739049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL300455A IL300455A (en) | 2020-08-21 | 2021-08-23 | New psilocin derivatives with prodromal properties |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230295086A1 (https=) |
| EP (1) | EP4200279A1 (https=) |
| JP (1) | JP2023538402A (https=) |
| KR (1) | KR20230054397A (https=) |
| CN (2) | CN116075499B (https=) |
| AU (1) | AU2021328726A1 (https=) |
| BR (1) | BR112023003153A2 (https=) |
| CA (1) | CA3188636A1 (https=) |
| CO (1) | CO2023003282A2 (https=) |
| GB (2) | GB2613993B (https=) |
| IL (1) | IL300455A (https=) |
| MX (1) | MX2023002133A (https=) |
| WO (1) | WO2022038299A1 (https=) |
| ZA (1) | ZA202301693B (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11974984B2 (en) | 2017-02-09 | 2024-05-07 | Caamtech, Inc. | Compositions and methods comprising a combination of serotonergic drugs |
| US12414936B2 (en) | 2017-02-09 | 2025-09-16 | Caamtech, Inc. | Compositions comprising a serotonergic tryptamine compound |
| CA3152752A1 (en) | 2019-10-01 | 2021-04-08 | Thomas Henley | Genetic engineering of fungi to modulate tryptamine expression |
| KR20220137081A (ko) | 2020-02-04 | 2022-10-11 | 마인드셋 파마 인크. | Cns 장애의 치료를 위한 세로토닌성 사이키델릭 작용제로서의 실로신 유도체 |
| EP4255422A4 (en) | 2020-12-03 | 2024-12-18 | Mydecine Innovations Group Inc. | NEW PSILOCIN ANALOGUE COMPOSITIONS AND METHODS OF THEIR SYNTHESIS |
| KR20230109765A (ko) * | 2020-12-09 | 2023-07-20 | 캄테크, 인크. | 다이알킬 트립타민 및 이의 치료적 용도 |
| EP4155306A1 (en) | 2021-01-15 | 2023-03-29 | Beckley Psytech Limited | Neuroactive ergoline analogue |
| US12534441B2 (en) | 2021-01-15 | 2026-01-27 | Beckley Psytech Limited | Tryptamine analogues |
| US11312684B1 (en) | 2021-02-10 | 2022-04-26 | Eleusis Therapeutics Us, Inc. | Pharmaceutically acceptable salts of psilocin and uses thereof |
| JP2024534801A (ja) * | 2021-08-20 | 2024-09-26 | テラン バイオサイエンシズ インコーポレイテッド | サイロシンのプロドラッグ及び誘導体ならびにその使用 |
| EP4452939A4 (en) * | 2021-12-24 | 2025-12-10 | Kuleon Llc | SEROTONINERGIC COMPOUNDS, POLYPODS, AND PROMEDICINAL PRODIGITS OF SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS |
| CN118984868A (zh) | 2021-12-31 | 2024-11-19 | 恩派瑞安神经科学公司 | 用于产生精神药物生物碱的遗传修饰的生物体 |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| AU2023234202A1 (en) * | 2022-03-18 | 2024-11-07 | Enveric Biosciences Canada Inc. | Salts of c4-carboxylic acid- and c4-carbonothioate-substituted tryptamine derivatives and methods of using |
| US11707447B1 (en) | 2022-03-18 | 2023-07-25 | Enveric Biosciences Canada Inc. | C4-carbonothioate-substituted tryptamine derivatives and methods of using |
| WO2023173196A1 (en) * | 2022-03-18 | 2023-09-21 | Enveric Biosciences Canada Inc. | C4-carboxylic acid-substituted tryptamine derivatives and methods of using |
| CA3248442A1 (en) * | 2022-04-13 | 2023-10-19 | Caamtech, Inc. | TRYPTAMINE DERIVATIVES |
| WO2023219789A1 (en) * | 2022-05-10 | 2023-11-16 | Mydecine Innovations Group Inc. | Novel psilocin prodrug compounds and methods of synthesizing the same |
| AU2023269880A1 (en) * | 2022-05-10 | 2024-01-18 | Mydecine Innovations Group Inc. | Novel psilocin prodrug compounds and methods of synthesizing the same |
| US11981637B2 (en) * | 2022-06-09 | 2024-05-14 | Caamtech, Inc. | 4-pivaloyloxy-n-methyltryptammonium chloride |
| AU2023319280A1 (en) * | 2022-08-05 | 2025-03-20 | Mindset Pharma Inc. | 3-ethylamino-indole dimers as serotonergic agents useful for the treatment of disorders related thereto |
| CN120091999A (zh) * | 2022-08-05 | 2025-06-03 | 思维模式制药公司 | 作为血清素能剂用于治疗相关病症的3-吡咯烷-吲哚二聚体 |
| US12264131B2 (en) | 2022-08-19 | 2025-04-01 | Beckley Psytech Limited | Pharmaceutically acceptable salts and compositions thereof |
| US20260085040A1 (en) * | 2022-09-12 | 2026-03-26 | Bionxt Solutions Inc. | Amino acid and carbohydrate psilocin derivatives |
| US20240269113A1 (en) * | 2023-01-24 | 2024-08-15 | Compass Pathfinder Limited | 3-(2-(DIMETHYLAMINO)ETHYL)-1H-INDOL-4-yl DERIVATIVES |
| US12246005B2 (en) | 2023-06-13 | 2025-03-11 | Beckley Psytech Limited | 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations |
| EP4592276A1 (en) | 2024-01-29 | 2025-07-30 | Universität Heidelberg | Novel acyloxymethyl prodrugs of psilocin and related 4-hydroxytryptamines obtained by an efficient synthetic approach |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3075992A (en) * | 1958-09-12 | 1963-01-29 | Sandoz Ltd | Esters of indoles |
| CH386442A (de) | 1959-03-18 | 1965-01-15 | Ciba Geigy | Verfahren zur Herstellung neuer 7-Aza-benzimidazole |
| US7655691B2 (en) * | 2004-09-27 | 2010-02-02 | Sard Howard P | Indole compounds useful as serotonin selective agents |
| CA2666149A1 (en) * | 2006-10-19 | 2008-04-24 | Auspex Pharmaceuticals, Inc. | Substituted indoles |
| US20180021326A1 (en) * | 2016-07-23 | 2018-01-25 | Paul Edward Stamets | Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin |
| CA3052974A1 (en) * | 2017-02-09 | 2018-08-16 | CaaMTech, LLC | Compositions and methods comprising a psilocybin derivative |
| KR20220137081A (ko) * | 2020-02-04 | 2022-10-11 | 마인드셋 파마 인크. | Cns 장애의 치료를 위한 세로토닌성 사이키델릭 작용제로서의 실로신 유도체 |
| JP2024534801A (ja) * | 2021-08-20 | 2024-09-26 | テラン バイオサイエンシズ インコーポレイテッド | サイロシンのプロドラッグ及び誘導体ならびにその使用 |
| US20240269113A1 (en) * | 2023-01-24 | 2024-08-15 | Compass Pathfinder Limited | 3-(2-(DIMETHYLAMINO)ETHYL)-1H-INDOL-4-yl DERIVATIVES |
| TW202525777A (zh) * | 2023-08-25 | 2025-07-01 | 英商康派斯開拓者公司 | ３－（２－（二甲基胺基）乙基）－１ｈ－吲哚－４－基衍生物 |
-
2021
- 2021-08-23 CA CA3188636A patent/CA3188636A1/en active Pending
- 2021-08-23 GB GB2304067.8A patent/GB2613993B/en active Active
- 2021-08-23 BR BR112023003153A patent/BR112023003153A2/pt unknown
- 2021-08-23 MX MX2023002133A patent/MX2023002133A/es unknown
- 2021-08-23 AU AU2021328726A patent/AU2021328726A1/en active Pending
- 2021-08-23 CN CN202180051296.8A patent/CN116075499B/zh active Active
- 2021-08-23 JP JP2023512327A patent/JP2023538402A/ja active Pending
- 2021-08-23 GB GB2412449.7A patent/GB2632056B/en active Active
- 2021-08-23 CN CN202510790017.XA patent/CN120904096A/zh active Pending
- 2021-08-23 WO PCT/EP2021/073303 patent/WO2022038299A1/en not_active Ceased
- 2021-08-23 EP EP21769676.4A patent/EP4200279A1/en active Pending
- 2021-08-23 KR KR1020237008542A patent/KR20230054397A/ko active Pending
- 2021-08-23 IL IL300455A patent/IL300455A/en unknown
- 2021-08-23 US US18/021,243 patent/US20230295086A1/en active Pending
-
2023
- 2023-02-10 ZA ZA2023/01693A patent/ZA202301693B/en unknown
- 2023-03-16 CO CONC2023/0003282A patent/CO2023003282A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2023003282A2 (es) | 2023-04-17 |
| WO2022038299A1 (en) | 2022-02-24 |
| JP2023538402A (ja) | 2023-09-07 |
| EP4200279A1 (en) | 2023-06-28 |
| CA3188636A1 (en) | 2022-02-24 |
| KR20230054397A (ko) | 2023-04-24 |
| MX2023002133A (es) | 2023-05-12 |
| CN120904096A (zh) | 2025-11-07 |
| BR112023003153A2 (pt) | 2023-04-04 |
| CN116075499B (zh) | 2025-07-25 |
| GB2613993B (en) | 2024-10-09 |
| GB2632056A (en) | 2025-01-22 |
| GB2613993A (en) | 2023-06-21 |
| GB202412449D0 (en) | 2024-10-09 |
| AU2021328726A1 (en) | 2023-03-02 |
| ZA202301693B (en) | 2026-01-28 |
| CN116075499A (zh) | 2023-05-05 |
| GB2632056B (en) | 2025-04-16 |
| US20230295086A1 (en) | 2023-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230295086A1 (en) | Novel psilocin derivatives having prodrug properties | |
| EP3336097B1 (en) | Preparation of the non-crystalline form of obeticholic acid | |
| US20230286975A1 (en) | Improved method for the production of lysergic acid diethylamide (lsd) and novel derivatives thereof | |
| US8829196B2 (en) | TRPA1 antagonists | |
| CN106456618A (zh) | 普多比啶类似物，其制备及用途 | |
| JP2005504042A (ja) | γセクレターゼインヒビターのようなスルホンアミド誘導体 | |
| JP2021531303A (ja) | エラゴリクスナトリウム組成物及び方法 | |
| US7091354B2 (en) | Processes for the preparation of peripheral opioid antagonist compounds and intermediates thereto | |
| KR20110089333A (ko) | 날메펜 히드로클로라이드 2수화물 | |
| CN117642396A (zh) | αVβ6和αVβ1整联蛋白抑制剂及其用途 | |
| EA051598B1 (ru) | Новые производные псилоцина, обладающие свойствами пролекарств | |
| CN104395333B (zh) | 改进的合成 | |
| BR122026001062A2 (pt) | Derivados de psilocina que apresentam propriedades pró-fármaco, seu uso e seu método de produção | |
| MXPA03011594A (es) | Un proceso para preparar paroxetina hc1 que limita la formacion de compuestos color rosa. | |
| US8710078B2 (en) | Crystalline solvates of 6-(piperidin-4-yloxy)-2H-isoquinolin-1-one hydrochloride | |
| HU228458B1 (en) | Duloxetine salts for producing pharmaceutical compositions | |
| KR20170143141A (ko) | 바레니클린 유리염기의 결정질 다형체, 이의 제조방법 또는 용도 | |
| HUE028550T2 (en) | Polymorphs of 6- (Piperidin-4-yloxy) -2H-isoquinolin-1-one hydrochloride | |
| WO2025031304A1 (en) | Bilobalide derivative compounds for treating neurological diseases and cancers | |
| WO2022191092A1 (ja) | キノリン化合物、ｈｎｍｔ阻害剤、及びａｄｈｄ、ナルコレプシー又はアルツハイマーの予防・治療剤 | |
| JP2001515067A (ja) | 結晶１０，１０−ビス（（２−フルオロ−４−ピリジニル）メチル）−９（１０ｈ）−アントラセノンおよびその改良製法 | |
| CN118525011A (zh) | 一种吗啉基喹唑啉类化合物、其制备方法及应用 | |
| CN113906016A (zh) | 选择性组胺h3拮抗剂酸加成盐及其制备方法 | |
| BR122021023465B1 (pt) | Derivado de pirazolopiridina, seu uso e composição farmacêutica | |
| NZ620864B2 (en) | Crystalline solvates of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride |